Skip to main content

Table 2 Relationship between TILs, PD-L1, and clinicopathological characteristics in post-neoadjuvant breast cancer cases

From: Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance

  TIL status   PD-L1 status  
Positive (N = 50) Negative (N = 8) p value Positive (N = 10) Negative (N = 48) p value
Age
  < 50 years 22 6 0.103 8 20 0.027a
 >50 years 28 2   2 28  
Size at surgery
  < 2 cm 19 5 0.191 7 17 0.043a
  > 2 cm 31 3   3 31  
Histotype
 Ductal 43 7 0.909 8 42 0.53
 Other 7 1   2 6  
Grade
 1 and 2 32 6 0.697 3 33 0.45
 3 20 2   6 15  
Lymph node status
 Positive 32 5 0.934 8 29 0.241
 Negative 18 3   2 19  
Hormone receptor status
 Positive 39 7 0.599 8 38 0.497
 Negative 10 1   1 10  
HER2 status
 Positive 10 2 0.745 2 10 0.952
 Negative 40 6   8 38  
Relapse status
 Relapse 9 2 0.37 11 0 0.159
 No relapse 23 2   21 4  
 N/A 27 4   16 6  
ΔTILs (pre–post)
 Positive or zero 15 5 0.01 19 1 0.206
 Negative 23 0   19 4  
  1. TIL tumor infiltrating lymphocyte, PD-L1 programmed death ligand 1, HER human epidermal growth factor, N/A not available
  2. aSignificant (p < 0.05)